Renal hemodynamic effect of cyclooxygenase 2 inhibition in young men and women with uncomplicated type 1 diabetes mellitus.
In experimental studies, cyclooxygenase 2 (COX2)-derived vasodilatory prostaglandins play a more prominent role in arterial vasoregulation in females. The gender-dependent effect of COX2 modulation in humans with type 1 diabetes mellitus (DM) is unknown. Accordingly, we examined the renal hemodynamic role of prostaglandins by assessing the response to COX2 inhibition in young men and women with type 1 DM. We also used a graded ANG II infusion to determine whether gender-based differences were mediated by effects of COX2 inhibition on the renin angiotensin system (RAS). We hypothesized that COX2 inhibition would be associated with preferential vasoconstriction in women and would augment their response to ANG II. Baseline renal function and the response to an ANG II infusion were assessed during clamped euglycemia, and again after COX2 inhibition (200 mg celecoxib daily for 14 days) in 12 men and 9 women after 1 wk on a controlled protein and sodium diet. COX2 inhibition was associated with increases in filtration fraction (P = 0.045) and renal vascular resistance and a decline in renal blood flow (P = 0.04) in women compared with men. Before COX2 inhibition, women exhibited a decline in glomerular filtration rate in response to ANG II. COX2 inhibition abolished this effect, whereas the response was not altered in men. In summary, COX2 inhibition was associated with hemodynamic effects that differed based on gender. The ANG II response suggests that with uncomplicated type 1 DM, prostaglandins may contribute to RAS-mediated gender differences. Our results are consistent with experimental data suggesting augmented female prostanoid dependence.
Cherney
David Z I
DZ
Division of Nephrology, Toronto General Hospital, 585 Univ. Ave., 8N-846, Toronto, Ontario, Canada M5G 2N2.
Scholey
James W
JW
Nasrallah
Rania
R
Dekker
Maria G
MG
Slorach
Cameron
C
Bradley
Timothy J
TJ
Hébert
Richard L
RL
Sochett
Etienne B
EB
Miller
Judith A
JA
D000293:Adolescent; D000328:Adult; D000804:Angiotensin II / Q000008:administration & dosage; D000068579:Celecoxib; D051546:Cyclooxygenase 2 / Q000378:metabolism*; D052246:Cyclooxygenase 2 Inhibitors / Q000008:administration & dosage*; D003922:Diabetes Mellitus, Type 1 / Q000188:drug therapy* / Q000503:physiopathology*; D003928:Diabetic Nephropathies / Q000188:drug therapy / Q000503:physiopathology; D005260:Female; D006801:Humans; D008297:Male; D011453:Prostaglandins / Q000652:urine; D011507:Proteinuria / Q000188:drug therapy / Q000503:physiopathology; D011720:Pyrazoles / Q000008:administration & dosage*; D012079:Renal Circulation / Q000187:drug effects*; D012727:Sex Characteristics; D013449:Sulfonamides / Q000008:administration & dosage*; D014662:Vasoconstrictor Agents / Q000008:administration & dosage; D014664:Vasodilation / Q000187:drug effects
D052246:Cyclooxygenase 2 Inhibitors; D011453:Prostaglandins; D011720:Pyrazoles; D013449:Sulfonamides; D014662:Vasoconstrictor Agents; D000804:Angiotensin II; D051546:Cyclooxygenase 2; D000068579:Celecoxib